- All > Medicine Access and Rational Use > Pricing
- All > Quality and Safety: Medicines > Quality Assurance
(2008; 62 pages)
Low-cost high-quality drugs benefit society and helps provide pharmaceutical companies a competitive edge. This study presents the issues that must be considered to achieve these common objectives in Bangladesh and explores options that the Government and the local industry could pursue.
Previous efforts to improve the drug quality in Bangladesh focused, without much success, on stricter regulation of the public market. This paper addresses this issue from a more private sector approach. The existing quality and price of pharmaceuticals are analyzed and alternative mechanisms are explored to improve the quality and cost competitiveness of Bangladesh’s pharmaceuticals domestically and internationally.
Pharmaceuticals are an extremely important part of health expenditures in Bangladesh. In 1997, more than $3.50 of a total annual per capita health spending of $10.60 was for pharmaceuticals (The World Bank 2001). The domestic pharmaceutical market in Bangladesh is cost-sensitive, protected from imports, and has a loose regulatory environment. While some domestic manufacturers produce pharmaceuticals of worldclass standards, others can and do flourish with a lower quality product...